Our expert trainer in Stem Cells, Erik Miljan, has recently published a journal discussing the development of pluripotent stem cells for vascular therapy
Peripheral arterial disease (PAD) is characterized by reduced limb blood flow due to arterial obstruction. Current treatment includes surgical or endovascular procedures, the failure of which may result in amputation of the affected limb. An emerging therapeutic approach is cell therapy to enhance angiogenesis and tissue survival. Small clinical trials of adult progenitor cell therapies have generated promising results, although large randomized clinical trials using well-defined cells have not been performed. Intriguing pre-clinical studies have been performed using vascular cells derived from human embryonic stem cells (hESC) or human induced pluripotent stem cells (hiPSCs). In particular, hiPSC-derived vascular cells may be a superior approach for vascular regeneration. The regulatory roadmap to the clinic will be arduous, but achievable with further understanding of the reprogramming and differentiation processes; with meticulous attention to quality control; and perseverance.
Click to view the full abstract
To request a full copy of the journal contact: email@example.com
Erik Miljan will be discussing the above issues and many more throughout the Stem Cells training course.
Attend one of his courses:
3 day MBA in Stem Cells – 18-20 June, Boston